These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 18761325

  • 1. Identification of novel selective V2 receptor non-peptide agonists.
    Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.
    Biochem Pharmacol; 2008 Oct 30; 76(9):1134-41. PubMed ID: 18761325
    [Abstract] [Full Text] [Related]

  • 2. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Oct 30; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 3. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL, Stoev S, Manning M, Derick S, Pena A, Mimoun MB, Guillon G.
    J Med Chem; 2004 Apr 22; 47(9):2375-88. PubMed ID: 15084136
    [Abstract] [Full Text] [Related]

  • 4. Position 4 analogues of [deamino-Cys(1)] arginine vasopressin exhibit striking species differences for human and rat V(2)/V(1b) receptor selectivity.
    Guillon G, Pena A, Murat B, Derick S, Trueba M, Ventura MA, Szeto HH, Wo N, Stoev S, Cheng LL, Manning M.
    J Pept Sci; 2006 Mar 22; 12(3):190-8. PubMed ID: 16130178
    [Abstract] [Full Text] [Related]

  • 5. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
    Laporte R, Kohan A, Heitzmann J, Wisniewska H, Toy J, La E, Tariga H, Alagarsamy S, Ly B, Dykert J, Qi S, Wisniewski K, Galyean R, Croston G, Schteingart CD, Rivière PJ.
    J Pharmacol Exp Ther; 2011 Jun 22; 337(3):786-96. PubMed ID: 21411496
    [Abstract] [Full Text] [Related]

  • 6. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
    Pena A, Murat B, Trueba M, Ventura MA, Wo NC, Szeto HH, Cheng LL, Stoev S, Guillon G, Manning M.
    J Med Chem; 2007 Feb 22; 50(4):835-47. PubMed ID: 17300166
    [Abstract] [Full Text] [Related]

  • 7. Short-term stimulation of the thiazide-sensitive Na+-Cl- cotransporter by vasopressin involves phosphorylation and membrane translocation.
    Mutig K, Saritas T, Uchida S, Kahl T, Borowski T, Paliege A, Böhlick A, Bleich M, Shan Q, Bachmann S.
    Am J Physiol Renal Physiol; 2010 Mar 22; 298(3):F502-9. PubMed ID: 20007345
    [Abstract] [Full Text] [Related]

  • 8. Small-molecule vasopressin-2 receptor antagonist identified by a g-protein coupled receptor "pathway" screen.
    Yangthara B, Mills A, Chatsudthipong V, Tradtrantip L, Verkman AS.
    Mol Pharmacol; 2007 Jul 22; 72(1):86-94. PubMed ID: 17435162
    [Abstract] [Full Text] [Related]

  • 9. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
    Slusarz MJ, Slusarz R, Ciarkowski J.
    Biopolymers; 2006 Apr 05; 81(5):321-38. PubMed ID: 16333859
    [Abstract] [Full Text] [Related]

  • 10. Characterization of a novel nonpeptide vasopressin V(2)-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes.
    Nakamura S, Yamamura Y, Itoh S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Ogawa H, Shinohara T, Kan K, Tanada Y, Teramoto S, Sumida T, Nakayama S, Sekiguchi K, Kambe T, Tsujimoto G, Mori T, Tominaga M.
    Br J Pharmacol; 2000 Apr 05; 129(8):1700-6. PubMed ID: 10780976
    [Abstract] [Full Text] [Related]

  • 11. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S, Hirano T, Tsujimae K, Aoyama M, Kondo K, Yamamura Y, Mori T, Tominaga M.
    J Pharmacol Exp Ther; 2000 Dec 05; 295(3):1005-11. PubMed ID: 11082435
    [Abstract] [Full Text] [Related]

  • 12. Recent patenting activities in the discovery and development of vasopressin V2 receptor agonists.
    Tsukamoto I.
    Expert Opin Ther Pat; 2012 Jun 05; 22(6):579-86. PubMed ID: 22630566
    [Abstract] [Full Text] [Related]

  • 13. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
    Tsukamoto I, Koshio H, Akamatsu S, Kuramochi T, Saitoh C, Yatsu T, Yanai-Inamura H, Kitada C, Yamamoto E, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2008 Nov 01; 16(21):9524-35. PubMed ID: 18835174
    [Abstract] [Full Text] [Related]

  • 14. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I, Koshio H, Kuramochi T, Saitoh C, Yanai-Inamura H, Kitada-Nozawa C, Yamamoto E, Yatsu T, Shimada Y, Sakamoto S, Tsukamoto S.
    Bioorg Med Chem; 2009 Apr 15; 17(8):3130-41. PubMed ID: 19321349
    [Abstract] [Full Text] [Related]

  • 15. The discovery of novel vasopressin V1b receptor ligands for pharmacological, functional and structural investigations.
    Guillon G, Derick S, Pena A, Cheng LL, Stoev S, Seyer R, Morgat JL, Barberis C, Gal CS, Wagnon J, Manning M.
    J Neuroendocrinol; 2004 Apr 15; 16(4):356-61. PubMed ID: 15089974
    [Abstract] [Full Text] [Related]

  • 16. Vasopressin receptors in voiding dysfunction.
    Pisipati S, Hashim H.
    Handb Exp Pharmacol; 2011 Apr 15; (202):453-83. PubMed ID: 21290239
    [Abstract] [Full Text] [Related]

  • 17. Design and synthesis of potent, highly selective vasopressin hypotensive agonists.
    Stoev S, Cheng LL, Manning M, Wo NC, Szeto HH.
    J Pept Sci; 2006 Sep 15; 12(9):592-604. PubMed ID: 16625682
    [Abstract] [Full Text] [Related]

  • 18. Comparative pharmacology of bovine, human and rat vasopressin receptor isoforms.
    Andrés M, Peña A, Derick S, Raufaste D, Trojnar J, Wisniewski K, Trueba M, Serradeil-Le Gal C, Guillon G.
    Eur J Pharmacol; 2004 Oct 06; 501(1-3):59-69. PubMed ID: 15464063
    [Abstract] [Full Text] [Related]

  • 19. New benzylureas as a novel series of potent, nonpeptidic vasopressin V2 receptor agonists.
    Yea CM, Allan CE, Ashworth DM, Barnett J, Baxter AJ, Broadbridge JD, Franklin RJ, Hampton SL, Hudson P, Horton JA, Jenkins PD, Penson AM, Pitt GR, Rivière P, Robson PA, Rooker DP, Semple G, Sheppard A, Haigh RM, Roe MB.
    J Med Chem; 2008 Dec 25; 51(24):8124-34. PubMed ID: 19053774
    [Abstract] [Full Text] [Related]

  • 20. Characterization of RWJ-351647, a novel nonpeptide vasopressin V2 receptor antagonist.
    Gunnet JW, Matthews JM, Maryanoff BE, de Garavilla L, Andrade-Gordon P, Damiano B, Hageman W, Look R, Stahle P, Streeter AJ, Wines PG, Demarest KT.
    Clin Exp Pharmacol Physiol; 2006 Apr 25; 33(4):320-6. PubMed ID: 16620295
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.